Pyruvate dehydrogenase complex (PDC) (PDC)

The pyruvate dehydrogenase complex (PDC) is a massive multi-enzyme assembly located in the mitochondrial matrix that serves as the primary gatekeeper of carbohydrate metabolism [1, 4]. It catalyzes the irreversible oxidative decarboxylation of pyruvate to form acetyl-CoA, effectively linking the glycolytic pathway in the cytosol to the tricarboxylic acid (TCA) cycle in the mitochondria [2, 5]. The complex consists of three main catalytic components—pyruvate dehydrogenase (E1), dihydrolipoyl transacetylase (E2), and dihydrolipoyl dehydrogenase (E3)—along with regulatory kinases and phosphatases [14]. Dysregulation of PDC is a hallmark of several metabolic disorders; for instance, its inhibition in cancer cells (the Warburg effect) promotes aerobic glycolysis, while its deficiency leads to congenital lactic acidosis and severe neurological impairment [6, 9]. In conditions like type 2 diabetes and heart failure, reduced PDC activity contributes to metabolic inflexibility and impaired energy production [2, 12]. Therapeutic strategies often focus on modulating PDC activity, such as using dichloroacetate to inhibit its regulatory kinases and restore oxidative metabolism in cancer or diabetes [8, 12]. Additionally, direct inhibitors like CPI-613 are being explored to disrupt the altered metabolism of tumor cells [13]. Cofactor supplementation with thiamine and lipoic acid is also a standard approach to support enzyme function in patients with genetic deficiencies [7]. Monitoring PDC activity and its phosphorylation status provides critical insights into a patient's metabolic state and response to therapy [14, 15].

Other names

Pyruvate dehydrogenasePDHPDHCPyruvate dehydrogenase (lipoamide) complexMitochondrial pyruvate dehydrogenase complex

Inhibition of pyruvate dehydrogenase kinase (PDK) to maintain the complex in its active, unphosphorylated state; direct inhibition of the E2 subunit to disrupt mitochondrial metabolism in cancer cells; and supplementation of essential cofactors (thiamine, lipoic acid) to enhance residual enzymatic activity in deficiency states [6, 7, 13].